anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Victoza
Trial phase: Phase 3
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 84
Group description: subcutaneous daily injection

liraglutide
Eligibility criteria:
Inclusion Criteria:

1) Type 1 Diabetes on continuous subcutaneous insulin infusion (CSII; also known as insulin pump) or multiple (four or more) injections of insulin per day. 2) Using a continuous glucose monitoring device (CGM) or regularly measuring their blood sugars four times daily. 3) HbA1c of less than 8.5%. 4) Well versed with carbohydrate counting. 5) Age 18-75 years 6) BMI≥ 25kg/m2 7) Age at diagnosis of type 1 diabetes should be <30 years. 8) evidence of auto-immunity to beta cells (GAD-65 and islet cell antibody screen)

Exclusion Criteria:

1)Type 1 diabetes for less than 6 months; 2)Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks; 3)Hepatic disease (transaminase > 3 times normal) or cirrhosis; 4)Renal impairment (serum eGFR <30ml/min/1.73m2); 5)HIV or Hepatitis B or C positive status; 6)Participation in any other concurrent clinical trial; 7)Any other life-threatening, non-cardiac disease; 8)Use of an investigational agent or therapeutic regimen within 30 days of study. 9) history of pancreatitis 10) pregnancy 11) inability to give informed consent 12) history of gastroparesis 13)history of medullary thyroid carcinoma or MEN 2 syndrome. 14) Smokers will be advised not to change their amount of smoking for the duration of the study; 15) Use of any agent other than insulin for treatment of diabetes (metformin, pramlintide or thiazolidinediones.
Intervention: Ranolazine
Trial phase: Phase 3
ATC code: C01EB18
SMILES: COc1ccccc1OCC(O)CN1CCN(CC(=O)Nc2c(C)cccc2C)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor.

Ranolazine: Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor.
Eligibility criteria:
Inclusion Criteria

type 1 or 2 diabetes mellitus
anginal symptoms and/or exertional dyspnea;
ability to exercise and achieve an exercise tolerance of at least 3 METS but not higher than 9 METS either on a treadmill or bicycle exercise tolerance test;
perfusion sum stress score (SSS) ≤ 6, as assessed by initial PET

Exclusion Criteria

patients not fulfilling inclusion criteria
patients with evidence of unprotected left main coronary artery stenosis >50%
patients with evidence of new obstructive CAD not on optimal medical therapy
evidence of angiographic disease and/or inducible myocardial ischemia on stress testing planning to undergo revascularization within the following 3 months
history of cardiomyopathy (LVEF <40%) or significant valvular heart disease
uncontrolled hypertension (SBP >180 mm Hg at screening)
gait instability, lower extremity amputations preventing exercise

9. significant liver dysfunction (LFTs >3x upper limits of normal), including cirrhosis 10. prolonged QT (QTc >450 and >470 ms for men and women, respectively) or concomitant use of drugs that prolong QT interval (including methadone and antiarrhythmics such as sotalol, amiodarone, and quinidine) 11. use of drugs that inhibit CYP3A such as ketoconazole, itraconazole, fluconazole, clarithromycin, erythromycin, diltiazem, verapamil, nefazodone, nelfinavir, ritonavir, lopinavir, ritonavir, indinavir, and saquinavir 12. use of drugs that induce CYP3A such rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort 13. atrial fibrillation / inability to hold breath for ≥ 10 seconds (in patients in whom CTA will be performed) 14. eGFR < 50 ml/min or end stage renal disease on dialysis 15. allergy to intravenous contrast 16. pregnant or lactating women, or women of childbearing potential not using an acceptable form of birth control (negative pregnancy test also required) 17. inability to fit safely in PET/CT scanner
Intervention: Enalapril
Trial phase: Phase 2
ATC code: C09AA02 | C09BA02 | C09BB02 | C09BB06
SMILES: CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Use of enalapril in subjects undergoing radiotherapy for lung cancer.

Enalapril: Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
Eligibility criteria:
Inclusion Criteria:

Men and women undergoing radiation therapy to the chest for cancer at the Baltimore, the Milwaukee, and Ann Arbor Veterans Affairs Hospital are eligible.
Subjects who require radiation therapy to attempt to cure or to palliate their disease will be eligible for this study.

Exclusion Criteria:

Subjects eligible for surgical resection and who do not need radiation therapy will not be eligible for this study.
Subjects who must remain on ACE inhibitors, angiotensin blockers, or renin antagonists will be excluded.
Intervention: ASCORBIC ACID
Trial phase: Phase 1 | Phase 2
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate

Dosage:

Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)

Ascorbic Acid + Sorafenib
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
Metastatic hepatocellular carcinoma
G6PD (glucose-6-phosphate dehydrogenase) status > lower limit of normal
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Laboratory at baseline evaluation for inclusion in the study: creatinine ≤1.5X upper limit (if the creatinine is elevated, but ≤1.5X the ULN, a 24 hour creatinine clearance will be obtained); transaminase (AST/ALT) ≤2.0X upper limit of normal; bilirubin levels ≥ 2 mg/dL; ANC ≥1,500/mm3; Hemoglobin > 8g/dL; platelet ≥ 100,000/mm3
Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the study.
Willing and able to provide informed consent and participate in the study procedures.

Exclusion Criteria:

Patients with evidence of a significant current psychiatric disorder that would prevent completion of the study as determined by the PI will not be allowed to participate.
Co-morbid medical condition that would affect survival or tolerance as determined by the PI. This includes patients who have not fully recovered from toxicities associated with prior therapy. It also includes subjects who, as determined by the PI, are at risk of experiencing fluid overload (i.e., congestive heart failure).
Patients who currently abuse alcohol or drugs.
Patients with known glomerular filtration rate of <60ml/min or with nephrotic range proteinuria.
Pregnant or lactating women
Enrollment in active clinical trial/ experimental therapy or IND study within the prior 30 days.
Contraindication for CT or PET/CT as per the PI.
Intervention: Cefazolin
Trial phase: Phase 4
ATC code: J01DB04
SMILES: [H][C@]12SCC(CSc3nnc(C)s3)=C(C(=O)O)N1C(=O)[C@H]2NC(=O)Cn1cnnn1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: 4 gram dose of pre-operative prophylaxis
Eligibility criteria:
Inclusion Criteria:

Age 18 years or above
Body mass index (BMI) of 35 or greater at the time of the first obstetric clinic visit
Undergoing cesarean delivery

Exclusion Criteria:

BMI less than 35.
Not undergoing Cesarean delivery.
Age less than 18 years.
Pre-existing infection.
Allergy to cephalosporin medications or a history of an anaphylactic reaction to penicillin.
Cesarean delivery being performed under emergent circumstances.
Intervention: Cefazolin
Trial phase: Phase 4
ATC code: J01DB04
SMILES: [H][C@]12SCC(CSc3nnc(C)s3)=C(C(=O)O)N1C(=O)[C@H]2NC(=O)Cn1cnnn1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: 2 gram dose of pre-operative cefazolin
Eligibility criteria:
Inclusion Criteria:

Age 18 years or above
Body mass index (BMI) of 35 or greater at the time of the first obstetric clinic visit
Undergoing cesarean delivery

Exclusion Criteria:

BMI less than 35.
Not undergoing Cesarean delivery.
Age less than 18 years.
Pre-existing infection.
Allergy to cephalosporin medications or a history of an anaphylactic reaction to penicillin.
Cesarean delivery being performed under emergent circumstances.
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 7
Group description: A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.

Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Eligibility criteria:
Inclusion Criteria:

Subject, parent, or guardian willing and able to give informed consent
NRS for pain over the past 24 hours >4 at baseline
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-20 years old

Exclusion Criteria:

If they are known or suspected to have drug addiction
Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder
Uncontrolled hypertension
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 7
Group description: A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.

Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Eligibility criteria:
Inclusion Criteria:

Subject, parent, or guardian willing and able to give informed consent
NRS for pain over the past 24 hours >4 at baseline
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-20 years old

Exclusion Criteria:

If they are known or suspected to have drug addiction
Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder
Uncontrolled hypertension
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 7
Group description: A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.

Ketamine: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Eligibility criteria:
Inclusion Criteria:

Subject, parent, or guardian willing and able to give informed consent
NRS for pain over the past 24 hours >4 at baseline
Chronic pain, which has been present for >3 months, or persisting longer than is normal for the underlying diagnosis
Chronic pain related to physiologic diagnoses including but not limited to: cancer, rheumatologic disease, sickle cell anemia, cystic fibrosis, pancreatitis, and neuromuscular disease (e.g. Duchenne muscular dystrophy)
Able to tolerate and cooperate with neurocognitive assessment
Age 8-20 years old

Exclusion Criteria:

If they are known or suspected to have drug addiction
Uncontrolled psychiatric disorder such as depression, schizophrenia, or bipolar disorder
Uncontrolled hypertension
Known liver disease or elevation of AST or ALT greater than 3 times the upper limit of normal.
Previous intolerance or allergic reaction to ketamine
Pregnancy
Use of CYP3A4 inhibitors or inducers within the 2-week period prior the study drug administration or within 5 half-lives of the respective medication, whichever is longer, until study conclusion.
Consumption of grapefruit or grapefruit products from at least 2 weeks prior to study drug administration until study conclusion.
Intervention: Sevoflurane
Trial phase: Phase 4
ATC code: N01AB08
SMILES: FCOC(C(F)(F)F)C(F)(F)F
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)

Sevoflurane: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
Eligibility criteria:
Inclusion Criteria:

Women
Age 18-64
Patients undergoing ambulatory surgery
ASA PS I, II

Exclusion Criteria:

Chronic opioid use
Pregnant patient

Drop Out : patient or surgeon request
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60

Propofol: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Eligibility criteria:
Inclusion Criteria:

Women
Age 18-64
Patients undergoing ambulatory surgery
ASA PS I, II

Exclusion Criteria:

Chronic opioid use
Pregnant patient

Drop Out : patient or surgeon request
Intervention: Albendazole
Trial phase: Phase 1
ATC code: P02CA03
SMILES: CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 55
Group description: Participants were orally administered with 400 mg Albendazole tablets manufactured under aqua based solvent condition as single dose treatment.
Eligibility criteria:
Inclusion Criteria:

Male aged from 18 years up to 40 years (inclusive).
Body mass index within the range of 19-24kg/m^2.
Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination.
Negative for serum hepatitis B surface antigen, hepatitis C antibody and antibody of HIV.

Exclusion Criteria:

Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
Substance abuse: Recent history (within the last year) of alcohol or other substance abuse or failed to pass drugs of abuse screen and/or alcohol screen test.

Disease

Current or recurrent disease that could affect the action, absorption or distribution of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, abnormal liver function tests, renal insufficiency, congestive heart failure);
Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures;
History of gastrointestinal bleeding or peptic ulcer;
Asthma
History of liver disease

Medication

Use of any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing
Current or regular use of any prescription or over-the-counter medication, any other ABZ containing products, and traditional Chinese medicine.

Smoking

Subjects who are current smokers or non-smokers of less than 3 months;
Prior (within seven days of dosing) or current use of any other nicotine containing products, including nicotine replacement therapy.

Blood

Blood donation ≥ 500 ml within 90 days before the first study session.
Plasma donation within the 90 days before the first study session.
Intervention: Albendazole
Trial phase: Phase 1
ATC code: P02CA03
SMILES: CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 56
Group description: Participants were orally administered with 400 mg Albendazole tablets manufactured under ethanol based solvent condition as single dose treatment.
Eligibility criteria:
Inclusion Criteria:

Male aged from 18 years up to 40 years (inclusive).
Body mass index within the range of 19-24kg/m^2.
Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination.
Negative for serum hepatitis B surface antigen, hepatitis C antibody and antibody of HIV.

Exclusion Criteria:

Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
Substance abuse: Recent history (within the last year) of alcohol or other substance abuse or failed to pass drugs of abuse screen and/or alcohol screen test.

Disease

Current or recurrent disease that could affect the action, absorption or distribution of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, abnormal liver function tests, renal insufficiency, congestive heart failure);
Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures;
History of gastrointestinal bleeding or peptic ulcer;
Asthma
History of liver disease

Medication

Use of any drug known to induce or inhibit hepatic drug metabolism in the 30 days prior to dosing
Current or regular use of any prescription or over-the-counter medication, any other ABZ containing products, and traditional Chinese medicine.

Smoking

Subjects who are current smokers or non-smokers of less than 3 months;
Prior (within seven days of dosing) or current use of any other nicotine containing products, including nicotine replacement therapy.

Blood

Blood donation ≥ 500 ml within 90 days before the first study session.
Plasma donation within the 90 days before the first study session.
Intervention: Colchicine
Trial phase: Phase 2
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Colchicine 0.6 mg PO BID

Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects not undergoing ablation.
Eligibility criteria:
Inclusion Criteria:

Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices. Diagnosis of AF will be made based on the 12 -lead surface ECG.
Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology laboratory for the procedure in sinus rhythm..
Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in the electrophysiology laboratory in atrial fibrillation .

Exclusion Criteria:

Abnormal liver function with elevated enzymes> 1.5 times the normal.
Abnormal kidney function with glomerular filtration rate < 50 ml/min
Increased levels of creatine kinase or known myopathy
Neutropenia
Known GI disorders
Women of childbearing age who have not had surgical sterilization and are not using oral contraceptives, or who's spouse has not had surgical sterilization will be excluded due to the length of the trial and the possibility that they could become pregnant after entry.
Pregnant and lactating women
Lactose intolerance
Known sensitivity, allergy, or contraindication to colchicine use
Intervention: Colchicine
Trial phase: Phase 2
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Colchicine 0.6 mg PO BID

Colchicine, 0.6 mg PO BID: Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo Subjects undergoing ablation.
Eligibility criteria:
Inclusion Criteria:

Group 1: Persistent or chronic AF presenting for evaluation in cardiology offices. Diagnosis of AF will be made based on the 12 -lead surface ECG.
Group 2: Paroxysmal AF scheduled to go AF ablation presenting to the electrophysiology laboratory for the procedure in sinus rhythm..
Group 3:Chronic AF scheduled to go clinically indicated AF ablation, and presenting in the electrophysiology laboratory in atrial fibrillation .

Exclusion Criteria:

Abnormal liver function with elevated enzymes> 1.5 times the normal.
Abnormal kidney function with glomerular filtration rate < 50 ml/min
Increased levels of creatine kinase or known myopathy
Neutropenia
Known GI disorders
Women of childbearing age who have not had surgical sterilization and are not using oral contraceptives, or who's spouse has not had surgical sterilization will be excluded due to the length of the trial and the possibility that they could become pregnant after entry.
Pregnant and lactating women
Lactose intolerance
Known sensitivity, allergy, or contraindication to colchicine use